Page last updated: 2024-09-05

tesaglitazar and Insulin Resistance

tesaglitazar has been researched along with Insulin Resistance in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (80.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hamrén, B; Karlsson, MO; Ribbing, J; Svensson, MK1
Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS1
Bamberg, K; Camejo, G; Dahllöf, B; Kjellstedt, A; Ljung, B; Oakes, ND; Ostling, J; Svensson, L1
Cooney, GJ; Furler, SM; Hegarty, BD; Kraegen, EW; Oakes, ND1
Camejo, G; Hultstrand, T; Jacinto, S; Ljung, B; Oakes, ND; Thalén, P; Wallin, B1
Cox, SL1
Boesten, LS; Camejo, G; Emeis, JJ; Havekes, LM; Jukema, JW; Kooistra, T; Lundholm, E; van Vlijmen, BJ; Zadelaar, AS1
Anzalone, D; Goldstein, BJ; Ohman, KP; Rosenstock, J; Tou, C1
Birketvedt, GS; Edwards, S; Fagerberg, B; Gause-Nilsson, I; Halldórsdóttir, S; Halmos, T; Lopatynski, J; Ohman, KP; Schuster, H; Stender, S; Tonstad, S1
Birketvedt, GS; Fagerberg, B; Gause-Nilsson, I; Ohman, KP; Schuster, H; Tonstad, S1

Reviews

2 review(s) available for tesaglitazar and Insulin Resistance

ArticleYear
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
    American heart journal, 2012, Volume: 164, Issue:5

    Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration

2012
Tesaglitazar: a promising approach in type 2 diabetes.
    Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:3

    Topics: Alkanesulfonates; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Insulin Resistance; Phenylpropionates; PPAR alpha; PPAR gamma

2006

Trials

3 trial(s) available for tesaglitazar and Insulin Resistance

ArticleYear
Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Current medical research and opinion, 2006, Volume: 22, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alkanesulfonates; Blood Glucose; Cholesterol, HDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma

2006
Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
    Atherosclerosis, 2008, Volume: 197, Issue:1

    Topics: Adult; Aged; Alkanesulfonates; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Humans; Insulin Resistance; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma

2008
Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
    Diabetes & vascular disease research, 2007, Volume: 4, Issue:3

    Topics: Adult; Alkanesulfonates; Blood Glucose; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenylpropionates; Postprandial Period; PPAR alpha; PPAR gamma; Triglycerides

2007

Other Studies

5 other study(ies) available for tesaglitazar and Insulin Resistance

ArticleYear
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:8

    Topics: Alkanesulfonates; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Models, Biological; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Predictive Value of Tests; Time Factors

2010
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
    Journal of lipid research, 2002, Volume: 43, Issue:11

    Topics: Alkanesulfonates; Animals; Bezafibrate; Carbohydrate Metabolism; Cinnamates; Diabetes Mellitus; Fatty Acids; Glucose; Humans; Insulin Resistance; Lipid Metabolism; Male; Mass Spectrometry; Mice; Mice, Obese; Molecular Structure; Obesity; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Cells, Cultured

2002
Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.
    Endocrinology, 2004, Volume: 145, Issue:7

    Topics: Adipose Tissue; Alkanesulfonates; Animals; Cinnamates; Dietary Fats; Fatty Acids, Nonesterified; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Phenylpropionates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2004
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 289, Issue:4

    Topics: Administration, Oral; Alkanesulfonates; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glucose; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Metabolic Syndrome; Obesity; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Treatment Outcome; Triglycerides

2005
Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
    Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:11

    Topics: Alkanesulfonates; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Biomarkers; Blood Vessels; Cell Adhesion; Cholesterol; Cholesterol, Dietary; Collagen; Dietary Fats; Female; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins; Macrophages; Mice; Mice, Transgenic; Monocytes; NF-kappa B; Phenylpropionates; PPAR alpha; PPAR gamma

2006